Regeneron Pharmaceuticals, Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
8
Buy
Overall
7.1
Buy
Quality
Health
Growth
Valuation
Sentiment
REGN
Clean balance sheet with low leverage (0.1× debt-to-equity).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
BUY
Target $877.73 (+24.5%)
28 analysts
BUY
Target $252.42 (+10.1%)
24 analysts
Fundamentals
REGN
JNJ
17.2×
Trailing P/E
26.5×
13.4×
Forward P/E
18.0×
29.6%
Profit Margin
21.8%
44.6%
Gross Margin
68.0%
14.5%
ROE
26.4%
19.0%
Revenue Growth
9.9%
-7.2%
Earnings Growth
-52.9%
0.40
Beta
0.33
—
Price / Book
—
$73.9B
Market Cap
$551.8B
$476 – $821
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.